Non-Small Cell Lung Cancer News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

New Data Show Benefit of Tagrisso in Patients with EGFR-mutated ... - Business Wire (press release)



New Data Show Benefit of Tagrisso in Patients with EGFR-mutated ... 
Business Wire (press release)
AstraZeneca today presented new data from a subgroup analysis of the Phase III FLAURA trial, which explored osimertinib as 1st-line therapy in patient.

and more » 


Roche chemo-immunotherapy combo mets NSCLC Phase III endpoint - European Biotechnology



European Biotechnology
 
Roche chemo-immunotherapy combo mets NSCLC Phase III endpoint 
European Biotechnology
Roche said it will submit the data of the open-label study, which enrolled 1.202 stage IV NSCLC patients, to the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) and file for global market approval of the combo as first-line ...
Roche says Tecentriq combination cuts lung cancer risk Reuters
Roche reshuffles lung cancer immunotherapy market with positive clinical trial results STAT
Phase III IMpower150 Study Showed Genentech's TECENTRIQ (atezolizumab) and Avastin (bevacizumab) Plus ... Business Wire (press release)
Endpoints News 
all 16 news articles » 


Osimertinib provides progression-free survival benefit to Asian ... - News-Medical.net



Osimertinib provides progression-free survival benefit to Asian ... 
News-Medical.net
Osimertinib improves progression-free survival compared to standard first line therapy in Asian patients with EGFR-mutated non-small-cell lung cancer (NSCLC) ...
New England Journal of Medicine Publishes Results of Phase III ... Business Wire India (press release)

all 3 news articles » 


Global Non-Small Cell Lung Cancer Epidemiology and Patient Flow Analysis - 2017 - PR Newswire (press release)



Global Non-Small Cell Lung Cancer Epidemiology and Patient Flow Analysis - 2017 
PR Newswire (press release)
The report provides insights into Non-Small Cell Lung Cancer epidemiology, Non-Small Cell Lung Cancer diagnosed patients, and Non-Small Cell Lung Cancer treatment rate for top seven pharmaceutical markets. The study measures key indicators such as ...

and more » 


Bevacizumab Does Not Improve Outcomes With Chemotherapy in Early NSCLC - Cancer Network



Bevacizumab Does Not Improve Outcomes With Chemotherapy in Early NSCLC 
Cancer Network
The addition of bevacizumab to adjuvant chemotherapy failed to improve survival outcomes in patients with surgically resected early-stage non?small-cell lung cancer (NSCLC), according to a new randomized trial. The agent ?does not have a role? in this ...

 


Non-Small Cell Lung Cancer Market Overview, Development 2017 to 2025 - Research of Market



Non-Small Cell Lung Cancer Market Overview, Development 2017 to 2025 
Research of Market
Non-Small Cell Lung Cancer-Mechanism of action Insights, 2017?, report provides comprehensive insights of the ongoing therapeutic research and development across Non-Small Cell Lung Cancer. The report provides a complete understanding of the ...

and more » 


Gene Profiling Uncovers Actionable Mutations in More Than Half of Non-Small Cell Lung Cancers - GenomeWeb



Curetoday.com
 
Gene Profiling Uncovers Actionable Mutations in More Than Half of Non-Small Cell Lung Cancers 
GenomeWeb
NEW YORK (GenomeWeb) ? Targeted sequencing matched mutations to therapeutic options in more than half of the non-small cell lung cancer patients analyzed in a new study. NSCLC accounts for 85 percent to 90 percent of the approximately 222,500 new ...
Clinical Trials Are Crucial in Mutation-Driven Lung Cancer Curetoday.com
High mutation burden improves nivolumab efficacy for small cell lung cancer Healio

all 7 news articles » 


Study: Alectinib 600 mg more effective than standard therapy in ... - News-Medical.net



Study: Alectinib 600 mg more effective than standard therapy in ... 
News-Medical.net
A subanalysis of the phase III ALEX study has shown that alectinib 600 mg twice daily is more effective than standard of care crizotinib in Asian patients with ...

and more » 


AstraZeneca to Present Transformative Data at ESMO Asia 2017 ... - Business Wire (press release)



AstraZeneca to Present Transformative Data at ESMO Asia 2017 ... 
Business Wire (press release)
At the ESMO Asia 2017 Congress in Singapore, 17-19 November 2017, AstraZeneca and MedImmune, its global biologics research and development arm, will ...

and more » 


Eli Lilly Drug Fails in Lung Cancer, Stalling Oncology Strategy - Xconomy



Xconomy
 
Eli Lilly Drug Fails in Lung Cancer, Stalling Oncology Strategy 
Xconomy
Indianapolis-based Lilly (NYSE: LLY) said Tuesday that its drug, abemaciclib (Verzenio), did not meet the Phase 3 study's main goal of improving overall survival in patients who have advanced non-small cell lung cancer. Abemaciclib targets two enzymes, ...